A Phase 3b, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants with Moderate-to-Severe Face and Neck Atopic Dermatitis
Solution for injectioncontaining the same excipients as the respective active lebrikizumab. Identical in appearance to test IMP. Supplied as a sterile PFS NSD.Ebglyss 250 mg solution for injection in pre-filled syringe
Eligibility
Age group
65+ years, 18-64 years, 0-17 years
Sex
Female, Male
Primary endpoint
Percentage of participants achieving an IGA score of 0 or 1 and a reduction ≥2 points from Baseline at Week 16
Endpoint detail
1. Percentage of participants with DLQI ≥4 points at Baseline achieving DLQI ≥4-point improvement from Baseline at Week 16, 2. Percentage change from Baseline to Week 16 in SCORing AD (SCORAD)
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.